Tracking anti-microbial resistance across care settings in Liverpool (TRACS- Liverpool) - Part 1
| ISRCTN | ISRCTN11601053 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11601053 |
| IRAS number | 309060 |
| Secondary identifying numbers | Sponsor 21-089, IRAS 309060, CPMS 51757 |
- Submission date
- 09/12/2021
- Registration date
- 17/12/2021
- Last edited
- 30/03/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English Summary
Background and study aims
This mixed methods study is the first stage of a programme of research looking at how antimicrobial resistance is acquired and transmitted within care settings in Liverpool.
Antimicrobial resistance (AMR) threatens the effectiveness of antibiotics that are widely used in modern medicine. Some resistant bacteria pose a particular threat, namely a group called Enterobacterales. These bacteria become resistant to antimicrobials when they acquire genes that enable the bacteria to produce enzymes that destroy antibiotics. People frequently carry these resistant bacteria without knowing. But in some cases they cause illness that can be life threatening or untreatable.
Although we understand how people can acquire these bacteria – either through direct exposure, such as swallowing them, or through exposure to antibiotics; it is less clear when and how these resistant bacteria are transmitted.
We know that people requiring frequent hospital admissions, or who live in long term care facilities are at particular risk of acquiring resistant bacteria.
We also know that rates of antimicrobial resistance are higher in the north-west than in the rest of the UK.
In order to be able to accurately plan and explore the problem of antimicrobial resistance locally we first need to understand it.
Who can participate?
Health professionals working in institutions that operate in Merseyside with knowledge and experience relevant to the research questions.
What does the study involve?
We will interview up to 50 key informants from local health and care organisations in order to gain a deeper understanding of how the hospital and care systems work locally. These participants will be identified by their key roles within health and care settings across Liverpool and will be invited to take part accordingly.
We will compare this information with specific datasets about antimicrobial resistant infection rates from selected local hospitals.
Combining these different sources of information will allow us to identify how and where potential transmission may be occurring. We can then accurately plan how to explore this further in the next stage of the research.
What are the possible benefits and risks of participating?
None
Where is the study run from?
Liverpool School of Tropical Medicine (UK)
When is the study starting and how long is it expected to run for?
October 2021 to September 2022
Who is funding the study?
UKRI Strength in Places Fund (UK)
Unilever (UK)
Who is the main contact?
Maria Moore, maria.moore@lstmed.ac.uk
Contact information
Public
Liverpool Life Sciences Accelerator - Room 321
Liverpool School of Tropical Medicine
Liverpool
L7 8XZ
United Kingdom
 ORCID ID |
0000-0001-6456-927X |
|---|---|
| Phone | +44 151 705 2566 |
| maria.moore@lstmed.ac.uk |
Scientific
Department of Clinical Infection, Microbiology and Immunity
University of Liverpool
8 West Derby Street
Liverpool
L69 7BE
United Kingdom
| ORCID ID |
0000-0002-3837-5188 |
|---|---|
| Phone | +44 151 795 9687 |
| jmlewis@liverpool.ac.uk |
Study information
| Study design | Observational cohort study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Cohort study |
| Study setting(s) | Other |
| Study type | Other |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet. |
| Scientific title | Tracking anti-microbial resistance across care settings in Liverpool (TRACS-Liverpool) Part 1: informing the design and development of an observational cohort study |
| Study acronym | TRACS - Liverpool: Part 1 |
| Study hypothesis | Rationale for the study: 1. To inform the development of survey questions for a future longitudinal cohort study. 2. To inform the development of the sampling and recruitment strategies for the longitudinal cohort study. 3. To estimate rates of ESBL-E/CPE acquisition and infection in two Liverpool acute hospitals to inform sample size calculations. 4. To scope and document relevant routine and secondary data sources on local ESBL-E/CPE transmission 5. To document key informants’ perspectives on the acceptability of the Part 2 study and how to improve it. 6. To map facility infrastructure, describe patient journeys within and between care facilities, and suggest how these might affect ESBL-E/CPE acquisition and prevention. 7. To review and summarise infection control policies for ESBL and CPE and suggest how these might be linked to protection from or acquisition of ESBL/CPE |
| Ethics approval(s) | Approved 16/02/2022, North West - Greater Manchester South Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ; +44(0)207 104 8143; gmsouthrec@hra.nhs.uk), ref:22/NW/0032 |
| Condition | Infection control |
| Intervention | Following enrolment participants will undertake a single semi-structured interview with the research team. This may be online or face-to-face. This will complete their involvement in the study. |
| Intervention type | Other |
| Primary outcome measure | 1.1. Estimate rates of ESBL-E/CPE acquisition and infection in two Liverpool acute hospitals, using readily available routine data sources at a single time point Measured using interviews at a single time point: 2.1. Scope and document relevant routine and secondary data sources on local ESBL-E/CPE transmission. 2.2. Document key informants’ perspectives on the acceptability of the Part 2 study and how to improve it. 2.3. Map facility infrastructure, describe patient journeys within and between care facilities, and suggest how these might affect ESBL-E/CPE acquisition and prevention. 2.4. Review and summarise infection control policies for ESBL and CPE and suggest how these might be linked to protection from or acquisition of ESBL/CPE |
| Secondary outcome measures | There are no secondary outcome measures |
| Overall study start date | 01/10/2021 |
| Overall study end date | 30/09/2022 |
Eligibility
| Participant type(s) | Health professional |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 45 |
| Participant inclusion criteria | 1. Male or female aged 18 years or above 2. Health professionals working in institutions that operate in Merseyside 3. Having knowledge and/or experience to share on the research questions 4. Able to facilitate access to relevant data required in the study 5. Willing and able to give informed consent for participation in the study |
| Participant exclusion criteria | 1. Not willing or available to participate in the study |
| Recruitment start date | 01/02/2022 |
| Recruitment end date | 30/04/2022 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Prescot Street
Liverpool
L7 8XP
United Kingdom
Liverpool
L1 2SA
United Kingdom
Sponsor information
University/education
1 Pembroke Place
Liverpool
L3 5QA
England
United Kingdom
| Phone | +44 151 705 3100 |
|---|---|
| info@lstmed.ac.uk | |
| Website | http://www.lstmed.ac.uk/ |
"ROR" |
https://ror.org/03svjbs84 |
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- UKRI
- Location
- United Kingdom
Government organisation / For-profit companies (industry)
- Alternative name(s)
- Unilever Global, Unilever PLC, U
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 30/09/2023 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journel. Dissemination of results amongst local stakeholders. |
| IPD sharing plan | Data sharing statement to be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 26/07/2023 | No | No |
Editorial Notes
30/03/2022: The ethics approval has been added.
11/01/2022: The CPMS number was added to the protocol/serial no. field.
17/12/2021: Trial's existence confirmed by NHS HRA.
